Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-103265B |
Brand: | MCE |
CAS: | - |
MDL | - |
---|---|
Molecular Weight | 834.61 |
Molecular Formula | C15H23Br2N5Na3O13P3 |
SMILES | O[C@H]1[C@@H](O[C@H](COP(OP(C(Br)(Br)P(O)(O[Na])=O)(O[Na])=O)(O[Na])=O)[C@H]1O)N2C3=NC=NC(N(CC)CC)=C3N=C2.O.[2.75] |
ARL67156 (FPL 67156) trisodium hydrate is a selective ecto-ATPase inhibitor. ARL67156 trisodium hydrate is a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K i s of 11, 18 and 12 μM, respectively. ARL67156 trisodium hydrate can be used in the research of disease like calcific aortic valve disease, asthma [1] [2] .
Ki: 11 μM (NTPDase1), 18 μM (NTPDase3), 12 μM (NPP1) [1]
ARL67156 trisodium hydrate (1-100 μM) potentiates neurogenic contractions in a concentration-dependent manner
[4]
.
ARL67156 trisodium hydrate (10 μg/mL, 24 h) increases the surface expression of CXCR3 on ATP-treated HMC-1 cells
[5]
.
ARL67156 trisodium hydrate (30 μM, 5s) potentiates the norepinephrine release promoted by ATP in guinea pig heart synaptosomes
[6]
.
ARL67156 trisodium hydrate (100 μM, 4h) significantly decreases HIV-1replication in macrophages
[7]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
ARL67156 trisodium hydrate (1.1 μg/kg/day, administered with osmotic pumps implanted subcutaneously, for 28 days) prevents the development of calcific aortic valve disease in Warfarin (HY-B0687)-treated rats
[2]
.
ARL67156 trisodium hydrate (intraperitoneal injection, 2 mg/kg) prevents the increase of serum adenosine concentration induced by Fructose 1,6-bisphosphate (FBP)
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Warfarin-induced mineralization rat model [2] |
Dosage: | 1.1 μg/kg/day |
Administration: | Administered with osmotic pumps implanted subcutaneously, for 28 days |
Result: |
Prevented the development of aortic stenosis by lowering the level of apoptosis and mineralization of the aortic valve/aorta.
Normalized the level of pAkt (an important kinase involved in the survival pathway). |
Animal Model: | C57BL/6 mice [3] |
Dosage: | 2 mg/kg |
Administration: | Intraperitoneal injection, 1 h before administration of FBP (100 mg/kg) |
Result: | Completely abolished the anti-inflammatory effects of FBP (observed by the neutrophil infiltration, hyperalgesia and oedema of the joint). |
Solid
Room temperature in continental US; may vary elsewhere.
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.